Research Article | Volume: 8, Issue: 11, November, 2018

3D-QSAR analysis of pyrimidine derivatives as AXL kinase inhibitors as anticancer agents

Siddharth J. Modi Vithal M. Kulkarni   

Open Access   

Published:  Nov 30, 2018

DOI: 10.7324/JAPS.2018.81103

AXL kinase receptor belongs to the TAM family of receptor tyrosine kinases (RTKs). Different types of cancer namely breast cancer, osteosarcoma, acute myeloid leukemia, colorectal cancer and non-small cell lung cancer (NSCLC) manifest overexpression of AXL receptor. Moreover, AXL kinase overexpression leads to tumor angiogenesis & resistance to chemotherapeutic agents and reduces the antitumor immune response. Therefore, AXL kinase has emerged as the potential and attractive target for the treatment of cancer. The present study is based on the correlation between the structural parameter and biological activity of the compounds using the 3D-QSAR technique. In this technique, pyrimidine derivatives and their inhibitory activity against AXL kinase receptor were chosen as independent and dependent variables respectively. Based on the investigation, the structural requirements for AXL kinase inhibition were recognized. Here, CoMFA and CoMSIA analysis were used for the execution of the 3D-QSAR model. The training and the test set pyrimidine derivatives were used for the generation and validation of QSAR model respectively. Dataset alignment was performed using the lowest energy conformer of the most active compound. CoMFA, as well as CoMSIA, model have encouraging values of the cross-validation coefficient (q2) 0.700 and 0.622 and conventional correlation coefficient (r2) 0.911 and 0.875 independently. Furthermore, values of r2pred were obtained as 0.709 and 0.668 respectively. Outcomes of the QSAR models and contour maps may be used for discovery of new AXL kinase inhibitors as potent anticancer agents.

Keyword:     AXL kinase receptor Pyrimidine derivatives 3D-QSAR CoMFA CoMSIA.


Modi SJ, Kulkarni VM. 3D-QSAR analysis of pyrimidine derivatives as AXL kinase inhibitors as anticancer agents. J App Pharm Sci, 2018; 8(11): 015-027.

Copyright: © The Author(s). This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text


Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood, 2013; 122(13):2443-52.

Buolamwini JK, Assefa H. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. Journal of medicinal chemistry, 2002; 45(4):841-52.

Bush BL, Nachbar RB. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. Journal of computer-aided molecular design, 1993; 7(5):587-619.

Clark M, Cramer RD, Van Opdenbosch N. Validation of the general purpose Tripos 5.2 force field. Journal of Computational Chemistry, 1989; 10(8):982-1012.

Cramer RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. Journal of the American Chemical Society, 1988; 110(18):5959-67.

Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clinical Cancer Research, 2010; 16(13):3507-16.

Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy. British journal of cancer, 2017; 116(4):415.

Golbraikh A, Tropsha A. Beware of q2!. Journal of molecular graphics and modelling, 2002; 20(4):269-76. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer. Nature Reviews Cancer, 2014; 14(12):769.

Hart CD, De Boer RH. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. OncoTargets and therapy, 2013; 6:1.

Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer letters, 2008; 268(2):314-24.

Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. Journal of medicinal chemistry, 1994; 37(24):4130-46.

Lai C, Gore M, Lemke G. Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene, 1994; 9:2567-78.

Lee HJ, Jeng YM, Chen YL, Chung L, Yuan RH. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis, 2013; 35(4):769-75.

Liu J, Zhang H, Xiao Z, Wang F, Wang X, Wang Y. Combined 3D-QSAR, molecular docking and molecular dynamics study on derivatives of peptide epoxyketone and tyropeptin-boronic acid as inhibitors against the β5 subunit of human 20S proteasome. International journal of molecular sciences, 2011; 12:1807-35.

Lu P, Wei X, Zhang R. CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV-1 integrase. European journal of medicinal chemistry, 2010; 45(8):3413-9.

Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene, 2007; 26(27):3909.

Makhija MT, Kulkarni VM. 3D-QSAR and molecular modeling of HIV-1 integrase inhibitors. Journal of computer-aided molecular design,2002; 16(3):181-200.

Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, et al. Design, synthesis, and biological evaluation of a series of novel AXL kinase inhibitors. ACS medicinal chemistry letters, 2011; 2(12):907-12.

Mori M, Kaneko N, Ueno Y, Tanaka R, Cho K, Saito R, et al. ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML). Clin Oncol, 2014; 32:7070.

Myint KZ, Xie XQ. Recent advances in fragment-based QSAR and multi-dimensional QSAR methods. International journal of molecular sciences, 2010; 11(10):3846-66.

O’Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Molecular and cellular biology, 1991; 11(10):5016-31.

Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, et al. AXL regulates mesothelioma proliferation and invasiveness. Oncogene, 2011; 30(14):1643.

Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, Gu X, et al. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene, 2013; 32(6):689.

Raichurkar AV, Kulkarni VM. Understanding the antitumor activity of novel hydroxysemicarbazide derivatives as ribonucleotide reductase inhibitors using CoMFA and CoMSIA. Journal of medicinal chemistry, 2003; 46(21):4419-27.

Sridhar J, Foroozesh M, Stevens CK. QSAR models of cytochrome P450 enzyme 1A2 inhibitors using CoMFA, CoMSIA and HQSAR. SAR and QSAR in Environmental Research, 2011; 22(7-8):681- 97.

SYBYL X Molecular Modeling Software, Tripos Associates, V. 2.0, St. Louis, USA, 2012; software available at

Yan SB, Peek VL, Ajamie R, Buchanan SG, Graff JR, Heidler SA, et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Investigational new drugs, 2013; 31(4):833-44.

Yuen HF, McCrudden CM, Huang YH, Tham JM, Zhang X, Zeng Q, et al. TAZ expression as a prognostic indicator in colorectal cancer. PloS one, 2013; 8(1):e54211.

Zhang Y, Tang YJ, Man Y, Pan F, Li ZH, Jia LS. Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis. International journal of immunopathology and pharmacology, 2013; 26(1):179-88.

Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature genetics, 2012; 44(8):852.

Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene, 2016; 35(21):2687.

Article Metrics

493 Absract views 40 PDF Downloads 533 Total views

   Abstract      Pdf Download

Related Search

By author names

Citiaion Alert By Google Scholar

Name Required
Email Required Invalid Email Address

Comment required